End organ damage in hypertension;Hypertoniebedingte endorganschäden

Deutsches Arzteblatt

Volumn 107, Issue 49, 2010, Pages 866-873

  Schmieder, Roland E ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTERIAL WALL THICKNESS; BLOOD PRESSURE REGULATION; CAROTID ARTERY; CEREBROVASCULAR DISEASE; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; KIDNEY DISEASE; MICROANGIOPATHY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASCULAR DISEASE;

CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; COMORBIDITY; EARLY DIAGNOSIS; HUMANS; HYPERTENSION; PREVALENCE; RISK ASSESSMENT; RISK FACTORS;

EID: 79751479592     PISSN: 00121207     EISSN: 01722107     Source Type: Journal    
DOI: 10.3238/arztebl.2010.0866     Document Type: Review

References (25)

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ: Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367: 1747-57.
2. Mancia G, Laurent S, Agabiti-Rosei E, et al.: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Foerce document. J Hypertens 2009; 27: 2121-58.
3. Deutsche Hochdruckliga e.V.: Leitlinien zur Behandlung der arteriellen Hypertonie. Nieren- und Hochdruckkrankheiten 2009; 38: 137-88.
4. Schmieder RE: The role of non-haemodynamic factors of the genesis of LVH. Nephrol Dial Transplant 2005; 20: 2610-2.
5. Laurent S, Boutouyrie P: Arterial stiffness: a new surrogate end point for cardiovascular disease? J Nephrol 2007; 20(suppl 12): 45-50.
6. Williams B, Lacy PS, Thom SM, et al.: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213-25.
7. Schmieder RE, Messerli FH: Hypertension and the heart. J Hum Hypertens 2000; 14: 597-604.
8. Motz W, Scheler S, Schwartzkopff B, Strauer BE: Evaluation of cardiac damage in hypertension. J Cardiovasc Risk 1995; 2: 16-26.
9. Schwab J, Schneider MP, Pauschinger M, Schmieder RE: Hypertension and diastolic dysfunction. MMW Fortschr Med 2009; 151: 41-3.
10. Okin PM, Jern S, Devereux RB, Kjeldsen SE, Dahlof B: Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients : the losartan intervention for endpoint (LIFE) reduction in hypertension study. Hypertension 2000; 35: 13-8. (Pubitemid 30054230)
11. Verdecchia P, Reboldi G, Gattobigio R, et al.: Atrial fibrillation in hypertension: predictors and outcome. Hypertension 2003; 41: 218-23. (Pubitemid 36204892)
12. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE: A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115: 41-6. (Pubitemid 36831120)
13. Verdecchia P, Angeli F, Borgioni C, et al.: Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens 2003; 16: 895-9. (Pubitemid 37315486)
14. Chen X, Wen W, Anstey KJ, Sachdev PS: Prevalence, incidence, and risk factors of lacunar infarcts in a community sample. Neurology 2009; 73: 266-72.
15. van den Born BJ, Hulsman CA, Hoekstra JB, Schlingemann RO, van Montfrans GA: Value of routine funduscopy in patients with hypertension: systematic review. BMJ 2005; 331: 73.
16. Michelson G, Welzenbach J, Pal I, Harazny J: Automatic full field analysis of perfusion images gained by scanning laser Doppler flowmetry. Br J Ophthalmol 1998; 82: 1294-300. (Pubitemid 28524125)
17. Zanchetti A, Mancia G, Black HR, et al.: Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. J Hypertens 2009; 27: 673-9.
18. Leoncini G, Ratto E, Viazzi F, et al.: Global risk stratification in primary hypertension: the role of the kidney. J Hypertens 2008; 26: 427-32. (Pubitemid 351317250)
19. Schmieder RE, Schrader J, Zidek W, et al.: Subclinical albuminuria, microalbuminuria and proteinuria-accepted cardiovascular risk markers? Dtsch Med Wochenschr 2006; 131: 2665-71.
20. Ninomiya T, Perkovic V, de Galan BE, et al.: Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009; 20: 1813-21.
21. Levey AS, Cattran D, Friedman A, et al.: Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2009; 54: 205-26.
22. Ibsen H, Olsen MH, Wachtell K, et al.: Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45: 198-202. (Pubitemid 40179960)
23. de Zeeuw D, Remuzzi G, Parving HH, et al.: Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921-7. (Pubitemid 39128617)
24. Ruggenenti P, Perna A, Benini R, Remuzzi G: Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). J Am Soc Nephrol 1998; 9: 2096-101. (Pubitemid 28482158)
25. Messerli FH, Mancia G, Conti CR, et al.: Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006; 144: 884-93.